Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourAscending Triangle
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $5.75
Key levels
Resistance$6.43
Resistance$5.92
Support$5.27
Support$4.25
Latest news & SEC filings
No headlines in the last 90 days.
Entrada Therapeutics is a drug developer focused on medicines that act on targets inside cells, using a peptide-based delivery technology to carry oligonucleotides and proteins into tissues. Its main programs are exon-skipping treatments for Duchenne muscular dystrophy, an eye disease candidate for a form of inherited vision loss, and a partnered program in a muscle disorder. The company runs studies in the U.S., U.K. and Europe.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$17.00
SEPT Mid Target
$20.00
SEPT High Target
$23.00
Analyst Consensus
$20.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TRDA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$18.61
12
Moat Score
NONE
2/9
Piotroski Score
0.2
Altman Z-Score
Insider Signal
SELLING
1 buys / 14 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Doshi Dipal | director officer | Sale | 8,724 | $62K | Sep 2, 2026 |
| MPM BIOVENTURES 2018, L.P. | 10% owner | Sale | 44,259 | $309K | Aug 31, 2026 |
| MPM BioVentures 2014, L.P. | 10% owner | Sale | 44,259 | $309K | Aug 31, 2026 |
| MPM BIOVENTURES 2018, L.P. | 10% owner | Sale | 3,733 | $26K | Aug 28, 2026 |
| MPM BioVentures 2014, L.P. | 10% owner | Sale | 3,733 | $26K | Aug 28, 2026 |
| MPM BIOVENTURES 2018, L.P. | 10% owner | Sale | 38,922 | $280K | Aug 27, 2026 |
| MPM BioVentures 2014, L.P. | 10% owner | Sale | 38,922 | $280K | Aug 27, 2026 |
| Zeiher Bernhardt G | director | Buy | 5,000 | $29K | May 20, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-87.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-306.55%
FCF Growth YoY
-189.7%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for TRDA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:51 | $5.44 | 1,382 | $$8K | BUY |
| 20:59:00 | $5.43 | 6,600 | $$36K | BUY |
| 20:55:13 | $5.43 | 5,215 | $$28K | SELL |
| 20:50:16 | $5.45 | 1,100 | $$6K | BUY |
| 20:50:16 | $5.45 | 1,400 | $$8K | BUY |
5 dark pool trades shown · $$85K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Entrada Therapeutics, Inc. (TRDA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Entrada Therapeutics, Inc. (TRDA) is at $5.31, down 2.39% (-$0.13) at the Nov 12, 2026 close.
The average analyst price target for TRDA is $20.00, ranging from $17 to $23, based on 2 analysts. Latest: Guggenheim maintains on Jun 8, 2026.
Analyst ratings for TRDA: 0 Buy, 2 Hold, 1 Sell — consensus Hold.
TRDA last reported on Aug 5, 2026: EPS -$1.01 vs -$1.05 expected — a beat of 3.7%.
TRDA does not currently pay a dividend.
Support: $5.27, $4.25. Resistance: $5.92, $6.43, $7.07.
Insider activity: SELLING, 1 buys and 14 sells in the last 90 days.